Wednesday Sep 10
Findings from University of California Provides New Data on...
The authors carried out studies to gain a better understanding of the drug loading, drug-release kinetics and cell-based efficacy of RBCm-cloaked NPs." The news reporters obtained a quote from the research from the University of , "Two strategies for loading doxorubicin into the RBCm-cloaked NPs were compared: physical encapsulation and chemical conjugation.
Mon Sep 08, 2014
Celsion Corporation Announces Highlights From Three Presentations...
The symposium, highly attended by physicians committed to HCC research, was conducted at the International Liver Cancer Association 7th Annual Conference from The presentations, covering new paradigms in staging HCC patients, Phase III studies in HCC, and advances in image guided radiofrequency ablation, were made on Queen Mary Hospital, Lead Asia Pacific Principal Investigator for Celsion's Phase III OPTIMA Study and member of the ILCA Governing Board. Professor Poon's presentation, titled " New Paradigms in Staging HCC: BCLC vs. Hong Kong Liver Cancer Staging System , " covered a more aggressive strategy for treating different stages of HCC.
Fri Sep 05, 2014
CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference
Live and archived webcasts of the presentations will be available on the company's website at www.cytrx.com/presentations . About currently is focused on the clinical development of aldoxorubicin , its improved version of the widely used chemotherapeutic agent doxorubicin.
Study Data from A. Latorre and Colleagues Update Understanding of...
Ideally, drugs are released in the target cells in response to cell specific intracellular triggers." The news correspondents obtained a quote from the research, "In this study, GNPs are loaded with doxorubicin or AZD8055, using a self-immolative linker which facilitates the release of anticancer therapeutics in malignant cells without modifications of the active compound.
Studies from Hokkaido University in the Area of Small Interference...
Editor at Biotech Week -- New research on Small Interference RNAs is the subject of a report. According to news reporting originating in , by NewsRx journalists, research stated, "It is well-known that renal cell carcinomas are resistant to classical cytotoxic anticancer drugs.
Reports Outline Multidrug Resistance Study Results from University...
We previously demonstrated that simultaneous delivery of the synergistic drugs doxorubicin and mitomycin C by polymer lipid hybrid nanoparticles circumvented MDR, increased efficacy, and reduced cardiotoxicity in immuncompromised mice superior to poly -coated lipososmal DOX ." The news reporters obtained a quote from the research from , "Herein it is shown that the DOX-MMC combination was also synergistic in MDR EMT6/AR1 murine breast cancer cells and that their nanoparticle formulations were able to overcome the MDR phenotype.
Studies from University of Nebraska Provide New Data on Breast Cancer ...
Poly -block-poly polymers were synthesized for preparing doxorubicin and lapatinib loaded micelles using a film dispersion method." The news reporters obtained a quote from the research from the , "Micelles were characterized by determining critical micelle concentration , particle size distribution, and drug loading.
Thu Sep 04, 2014
New Findings on Breast Cancer from Koch Institute for Integrative...
Layer-by-layer films were formed on nanoparticles by alternately depositing siRNA and poly-l-arginine; a single bilayer on the nanoparticle surface could effectively load up to 3500 siRNA molecules, and the resulting LbL nanoparticles exhibit an extended serum half-life of 28 h." Our news editors obtained a quote from the research from , "In animal models, one dose via intravenous administration significantly reduced the target gene expression in the tumors by almost 80%.
Reports Summarize Doxorubicin Therapy Findings from Middle East...
In an ideal targeted drug delivery system carrier nanoparticles would be directed to the tumor tissue and selectively release therapeutic molecules." Our news journalists obtained a quote from the research from , "As a novel approach, chitosan coated magnetic nanoparticles maintain a pH dependent drug delivery which provides targeting of drugs to the tumor site under a magnetic field.
Applied Clinical Trials
Celsion Reports Consolidated Duke University and Celsion's DIGNITY...
ThermoDox Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients Reinforces Current Phase II Interim Response Rates in Heavily Pretreated Patients, Further Supporting Continued Development Plans Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia /PRNewswire/ -- September 4, 2014 /PRNewswire/ -- Celsion Corporation today announced that data from two Phase I studies on ThermoDox in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia .
Wed Sep 03, 2014
Celsion Corporation Announces Enrollment Of First Patient In Global...
Celsion Corporation Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of ThermodoxA In Primary Liver Cancer , Sept.
Sat Aug 30, 2014
Fri Aug 29, 2014
CFDA approves BTG bead delivery device for liver cancer
BTG has received approval from the China FDA for a liver cancer treatment which uses its hydrogel product DC Beads.
Wed Aug 27, 2014
Findings on Doxorubicin Therapy Detailed by Investigators at Wuhan...
Instead of chemical bonding, doxorubicin , a low water solubility anticancer drug, was loaded in the pores of the modified IOPNR because of their porous structure and high porosity."
Thu Aug 21, 2014
The American Journal of Managed Care
Velcade: A Progress Report in Various Cancers
Bortezomib is approved in the United States for relapsed MCL. This study, registered as a collaborative trial between Millennium Pharmaceuticals and Johnson & Johnson Pharmaceuticals, evaluated whether replacing vincristine with bortezomib in R-CHOP improves outcomes in newly diagnosed, BMT-ineligible MCL patients.